Cell and Gene Therapy Bio-manufacturing Market Exhibiting a CAGR of 11.25% to 2031 | Latest InsightAce Study Reveals
InsightAce Analytic Pvt. LTd.
6 min read
InsightAce Analytic Pvt. LTd.
Companies Covered in this Study are Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Danaher Corporation, Endress+Hauser Group Services AG (Analytik Jena GmbH)
Jersey City, NJ, April 05, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy Bio-manufacturing Market Size, Share & Trends Analysis Report By Product Type (Consumables, Equipment, And Software Solutions), Usage (Commercial-Stage Manufacturing And Research-Stage Manufacturing), Application (Upstream Processing, Harvesting, And Downstream Processing), And End-User (Life Science Companies, Contract Research Organizations (Cros), Contract Manufacturing Organizations (CMOs), And Cell Banks)- Market Outlook And Industry Analysis 2031"
The global cell and gene therapy bio-manufacturing market is estimated to reach over USD 29.34 billion by 2031, exhibiting a CAGR of 11.25% during the forecast period 2023-2031.
The increased number of authorized medicines and growing infrastructure needs are likely to drive expansion in the global cell and gene therapy bio-manufacturing market. Furthermore, the increase in cell and gene therapy target indications creates a demand for large-scale bio-manufacturing. Further reasons driving cell and gene therapy manufacturing expansion include significant investments by government bodies and prominent market participants.
Over the previous decade, around USD 2.3 billion has been spent on gene therapy firms. This astronomical sum implies that significant pharmaceutical and biotechnology corporations are investing in top gene therapy businesses. Large service providers, such as CDMOs/CMOs and in-house manufacturers, see gene and cell therapy as an active investment sector.In addition, pharmaceutical and biotechnology businesses are investing heavily in cell and gene therapy research and development. The USFDA (United States Food and Drug Administration) reports a significant increase in cell and gene therapy items entering early development. Because of the factors mentioned above, the market is expected to raise at a healthy rate during the forecast period.
Recent Developments:
In January 2022, AllogeneTherapeutics Inc and AntionBiosciences Inc. formed an exclusive collaboration and global license agreement for Antion's miRNA technology (miCAR) to advance multiplex gene silencing as an additional tool in the development of next-generation allogeneic CAR T products.
List of Prominent Players in the Cell and Gene Therapy Bio-manufacturing Market:
Becton, Dickinson and Company
Endress+Hauser Group Services AG (Analytik Jena GmbH)
Cell and Gene Therapy Bio-Manufacturing Market Report Scope:
Report Attribute
Specifications
Market size value in 2022
USD 11.42 Bn
Revenue forecast in 2031
USD 29.34 Bn
Growth rate CAGR
CAGR of 11.25% from 2023 to 2031
Quantitative units
Representation of revenue in US$ Billion, and CAGR from 2023 to 2031
Historic Year
2019 to 2022
Forecast Year
2023-2031
Report coverage
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends
Segments covered
Product Type, Usage, Application, And End-User
Regional scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia
Market Dynamics:
Drivers:
The growing frequency of cancer and other target diseases and increased R&D investments in pharmaceutical companies are driving market expansion. The International Agency for Research on Cancer (IARC) updated GLOBOCAN 2020 with fresh cancer burden estimates, indicating that the number has climbed to 19.3 million cases. As the number of instances increases, so will the reliance on gene therapy, supporting market growth. Similarly, according to a paper released in October 2021 by the Journal of Orthopedic Surgery and Research titled "The Worldwide Prevalence of Osteoporosis in the World:
A Comprehensive Systematic Analysis and Meta-analysis," the global prevalence of osteoporosis was reported to be 18.3%. Stem cell treatment for osteoporosis has the potential to lower fracture susceptibility. As the prevalence of orthopedic illnesses rises, so will the demand for cell and gene therapy manufacturing services.
Challenges:
One of the most significant problems is the high cost of all medicines, which has financial repercussions for patients, prayers, and providers and is projected to impede market expansion. For instance, in May 2022, the US FDA approved chimeric antigen receptor T-cell therapy for treating pediatric and young adult patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia, and a single infusion costs roughly USD 475,000. As a result, such therapies have seen limited adoption, restricting market growth.
Regional Trends:
The North America Cell and Gene Therapy Bio-manufacturing Market is expected to register a substantial market share in revenue and is projected to expand at a increased CAGR soon due to the increasing prevalence and incidence of infectious diseases in this region as the elderly population grows. While gene treatments are widely employed in diagnostic, therapeutic, drug development, and other research for oncology and other clinical illnesses, the United States is the most affected country in the world. As a result, the demand for the same will be substantially higher in the North American region, where the patient population is growing faster than in other countries.
Segmentation of Cell and Gene Therapy Bio-manufacturing Market-
By Product Type-
Consumables
Culture Supplements
Media
Serum
Macronutrients
Single-Use Liquids
Cell Culture Reagents
Cell Quantification Kits
Equipment
Bioreactors/Fermenters
Continuous Bioreactors
Single-Use Bioreactors
Mixing Systems
Cell Counters
Cell Sorters
Centrifuges
Incubators
Biosafety Cabinets
Freezers
PCR Systems
Transfection Systems
Storage Tanks
Others
Software Solutions
By Usage-
Commercial Stage Manufacturing
Research Stage Manufacturing
By Application-
Upstream Processing
Formulation and Hydration
Cell Culture Processing
Harvesting
Downstream Processing
Separation and Filtration
Fill and Finish Operations
By End-User-
Life Science Companies
Equipment
Consumables
Software Solutions
Contract Research Organizations (CROs)
Equipment
Consumables
Software Solutions
Contract Manufacturing Organizations (CMOs)
Equipment
Consumables
Software Solutions
Cell Banks
Equipment
Consumables
Software Solutions
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of the Middle East and Africa
About Us:
InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.
